Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Kappos, Ludwig; Polman, Chris H.; Freedman, Mark S.; Edan, Gilles; Hartung, HP; Miller, David H.; Montalbán, Xavier; Barkhof, Frederik; Bauer, Lars; Jakobs, Peter; Pohl, Christoph; Sandbrink, Rupert

doi:10.1016/j.ajo.2006.11.003

Cited by 275 publications

(336 citation statements)

References 22 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…[19][20][21][22][23][24][25][26] Interferon beta-1b SC has been shown to delay sustained neurologic deterioration in patients with secondary progressive MS (SPMS). 27 Effective communication between the MS patient and the prescribing neurologist is essential in making decisions regarding the initiation and continuation of DMTs.…”

Section: Discussionmentioning

confidence: 99%

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Alroughani

Thussu

2012

International Journal of MS Care

View full text Add to dashboard Cite

The aim of this retrospective study was to determine the rate of nonadherence to disease-modifying therapies (DMTs) among multiple sclerosis (MS) patients in Kuwait and to identify reasons for patient discontinuation of long-term therapy. Using a newly established MS registry at our institution, we collected data on MS patients' demographics, clinical characteristics, disability measures, and continuation or discontinuation of first-line DMTs. Reasons for nonadherence were divided into four categories: adverse events, inconvenience, perceived lack of efficacy, and physician-documented disease progression. Of 212 eligible patients, 40.1% were found to be nonadherent to first-line DMTs. In the nonadherent group, the female-to-male ratio was 1.75:1 and the mean age at disease onset was 26.8 years. Of this group, 69.4% of patients had a relapsing-remitting course, 18.8% had a secondary progressive course, and 11.8% had clinically isolated syndrome. Compared with the adherent group, the nonadherent group had a shorter mean disease duration (P = .014) and a greater likelihood of having Expanded Disability Status Scale (EDSS) scores of 3 or lower (67.1% vs. 48.0%; P = .007). Inconvenience was the most common reason for nonadherence (32.9%), followed by perceived lack of efficacy (25.9%), adverse events (23.5%), and physician-documented disease progression (17.7%). In summary, the rate of nonadherence to first-line DMTs in MS patients at our institution is considered high. Most nonadherent patients had a short disease duration and low EDSS scores. Inconvenience and perceived lack of efficacy were the most common reasons for nonadherence. The results demonstrate a need to improve treatment adherence among MS patients in Kuwait through providing better patient education, improving communication between patients and health-care providers, defining therapy expectations, and instituting new therapeutic techniques. Int J MS Care. 2012;14:17-24.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Alroughani

Thussu

2012

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…In February 2002, the Betaferon in Newly Emerging MS for Initial Treatment (BENEFIT) trial began enrolling participants with first neurological events suggestive of MS (CIS) and characteristic MRI lesions within 60 days of onset [26]. Participants were randomized to IFN beta-1b 250 μg SC QOD or placebo in a 5:3 ratio.…”

Section: Clinically Isolated Syndromementioning

confidence: 99%

Interferon Beta and Glatiramer Acetate Therapy

McGraw

Lublin

2013

Neurotherapeutics

View full text Add to dashboard Cite

“…33 The Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment study (BENEFIT) randomized 487 patients to receive either IFN␤1b 250 g or placebo subcutaneously in a 5:3 ratio. 34 Enrollment was permitted up to 60 days after onset of the first clinical event, and dose titration was performed over the first 16 injections to optimize tolerability of the treatment. The use of a standardized steroid treatment for the CIS was at the discretion of the investigator.…”

Section: Clinically Isolated Syndromesmentioning

confidence: 99%

Interferon-β Treatment for Multiple Sclerosis

Bermel

Rudick

2007

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-␤, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in early, active patient populations have established the clinical efficacy of interferon-␤ in reducing relapses and delaying disability progression. Although its mechanism of action remains incompletely understood, a reduction in active lesions seen on magnetic resonance imaging implies primary anti-inflammatory properties, a mechanism supported by basic immunologic research. Variation in individual patient responsiveness to interferon-␤ may be due to disease variability or differential induction of interferon-stimulated genes. The magnitude of the therapeutic effect appears to be similar among products, but the optimal dose, route, and frequency of administration of the drug remain uncertain.

show abstract

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Cited by 275 publications

References 22 publications

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Interferon Beta and Glatiramer Acetate Therapy

Interferon-β Treatment for Multiple Sclerosis

Contact Info

Product

Resources

About